We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock
YARW

45 hedge funds and large institutions have $68.4M invested in Yarrow Bioscience, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

7% more funds holding

Funds holding: 42 → 45 (+3)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $161M → $68.4M (-$92.3M)

Holders
45
Holders Change
+3
Holders Change %
+7.14%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
12
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$5.6M
2
First Manhattan
First Manhattan
New York
+$2.35M
3
DCM
DAFNA Capital Management
California
+$1.41M
4
AIM
Alambic Investment Management
California
+$1.07M
5
JP Morgan Chase
JP Morgan Chase
New York
+$739K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$4.66M
2
RSCM
Rock Springs Capital Management
Maryland
-$3.25M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$2.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.86M
5
NHAS
Novo Holdings A/S
Denmark
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
51
PNC Financial Services Group
Pennsylvania
$2K – – –
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$1.57K – – –
Barclays
53
Barclays
United Kingdom
$1K -$22.4K -1 Closed
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$1K – – –
Fidelity Investments
55
Fidelity Investments
Massachusetts
$1K – – –
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$1K – – –
O
57
OrbiMed
New York
– -$4.66M -131 Closed
RSCM
58
Rock Springs Capital Management
Maryland
– -$3.25M -92 Closed
SSA
59
Schonfeld Strategic Advisors
New York
– -$493K -14 Closed
BFM
60
Boothbay Fund Management
New York
– -$315K -9 Closed
TCM
61
Tekla Capital Management
Massachusetts
– -$244K -7 Closed
ARTA
62
A.R.T. Advisors
New York
– -$179K -5 Closed
TCIM
63
TIAA CREF Investment Management
New York
– -$184K -5 Closed
TI
64
Trexquant Investment
Connecticut
– -$151K -4 Closed
VF
65
Virtu Financial
New York
– -$126K -4 Closed
PCM
66
Prelude Capital Management
New York
– -$1K – –
1 2
3

YARW Hedge Fund Activity: Q4 2018 in Review

45 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new YARW positions and 10 closed out — a net gain of 3 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.

  • 45 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2018, up from 42 in Q3 2018.
  • Funds reported $68.4M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2018, down 57% quarter-over-quarter.
  • 13 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2018 and 10 closed out, a net change of +3 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.

Based on aggregated 13F filings for Q4 2018.